Ketek safety committee review
FDA's Anti-Infective Drugs and Drug Safety & Risk Management Committees will review the benefit/risk profile of Sanofi-Aventis' antibiotic Ketek (telithromycin) during a Dec. 14-15 meeting. Labeling for Ketek was updated in June to include strengthened liver toxicity warnings (1"The Pink Sheet" July 3, 2006, p. 7). The meeting will be held at the Crowne Plaza in Silver Spring, Md., beginning at 8 a.m. both days. [Editor's note: To 2watch a webcastor order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com.]...
You may also be interested in...
Sanofi-Aventis is making a relatively modest labeling change to its antibiotic Ketek (telithromycin) following reports of hepatoxicity
CHF Solutions adds “CEO” to its president’s job title; Agilent VP of business development promoted to senior VP; Zimmer hires chief transformation officer; and more.
Pfizer has pressed on with the launch of a fourth biosimilar pegfilgrastim product, Nyvepria (pegfilgrastim-apgf), according to an investment bank. With Amgen continuing to hold more than 70% of the market, there is opportunity for Pfizer to capture significant market share.